Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
Abbreviations
Keywords
Cited by (0)
Chris Twelves is Professor of Clinical Cancer Pharmacology and Oncology and Head of Clinical Cancer Research Groups at the Leeds Cancer Research UK Centre. He is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer. After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre before taking up his current post at the University of Leeds and St James’s Institute of Oncology. Prof Twelves also heads the Leeds Experimental Cancer Medicine Centre in Leeds and has been a member of the Cancer Research UK New Agents Committee and Chair of the New Drug Development group of the EORTC. He has been involved in the development of several important new agents including capecitabine, and eribulin. Professor Twelves has published over 150 papers in journals including the New England Journal of Medicine, Lancet and Journal of Clinical Oncology and spoken at numerous international meetings. He has also edited, or contributed to, several books.
Maria Jove studied medicine at the University of Barcelona, Spain. She completed her specialization in medical oncology within the Spanish registrar program in 2012 at “Institut Catala d’Oncologia”, Barcelona. Maria worked as a Clinical Fellow in this institute for two years in the Lung and the Sarcoma/Genitourinari groups before moving to the UK to take up a position in St James’s University Hospital in Leeds as a Clinical Fellow in the Phase 1 unit under the supervision of Professor Christopher Twelves. Maria has also been involved with the Neuro-oncology and the Breast Cancer Groups under the supervision of Professor Susan Short and Professor Twelves, respectively. In April 2015 Maria commenced her PhD project, “Intratumoral drug penetration and distribution”, with the Pharmacokinetics Group (Lead, Professor Paul Loadman) at the Institute of Cancer Therapeutics (Hon Clinical Director, Professor Twelves) in Bradford, for which she received a grant from the Spanish Medical Oncology Society. Maria is a certified member of the ESMO and Spanish Medical Oncology Society.
Andrea Gombos is medical oncologist working for five years at the Institut Jules Bordet in Brussles. Her research activity is mainly focused on the coordination as principal investigator of several academic trials and internationally conducted clinical trials, evaluating new treatments and treatment combinations in the management of metastatic and early stage breast cancer. She is involved in the development of some international trials and is coordinator for a multicentre Belgian project including a large translational part aiming to understand resistance to the mTOR inhibitor everolimus in metastatic breast cancer. She is a certified member of the ESMO and full member of AACR.
Ahmad Awadais the Head of Medical Oncology Clinic Jules Bordet Cancer Institute Brussels, Belgium Professor Ahmad Awada was born in Lebanon and studied Medicine at the Université Libre de Bruxelles (ULB), Belgium. He did a specialisation in Internal Medicine and Medical Oncology at Jules Bordet Institute (under the supervision of Professor Jean Klastersky), in Brussels, until 1992 (“La plus grande distinction”). During his specialisation, he also had training in the clinical development of new anticancer drugs. As a research fellow, he worked in the Netherlands (New Drug Development Office, Free University, Amsterdam) and in San Antonio, USA (Institute for Drug Development). He focused on the clinical development of new anticancer agents. Back from the USA at the beginning of 1994, Dr. Awada became Assistant Head of Medical Oncology Clinic, and Head of the New Drugs Development Unit at Jules Bordet Institute, Brussels. Since April 2005, he has been the Head of the Medical Oncology Clinic. In addition and from 1st March 2011, Dr Awada was appointed Associate Head of Medicine Department. He has an important clinical activity in the treatment of solid tumors and in particular breast cancer. Dr. Awada took an active part in the development of new drugs, some of them already widely used, namely molecular-targeted therapies. Dr. Awada is a member of several international scientific (ASCO, EORTC, ESMO) societies and and Professor of Clinical Medicine at the Université Libre de Bruxelles. He published 26 book chapters and, 221 articles in international publications.